Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 11/20 | 0.57 |
| ▸ | MAPK13 | O15264 | 7/20 | 0.57 |
| ▸ | CDK8 | P49336 | 2/20 | 0.53 |
| ▸ | CCNC | P24863 | 1/20 | 0.49 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.48 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.48 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3174490 | 0.92 | CDK8 (0.53) | MAPK14MAPK13CDK8CCNCMAPK12 | |
| SCHEMBL378881 | 0.91 | CDK8 (0.63) | MAPK14MAPK13CDK8CCNCMAPK12 | |
| SCHEMBL3181946 | 0.91 | CDK8 (0.52) | MAPK14MAPK13CDK8CCNCMAPK12 | |
| SCHEMBL3174427 | 0.88 | CDK8 (0.53) | MAPK14MAPK13CDK8CCNCMAPK12 | |
| SCHEMBL3174282 | 0.87 | CDK8 (0.52) | MAPK14MAPK13CDK8CCNCMAPK12 | |
| SCHEMBL3390231 | 0.85 | CDK8 (0.50) | MAPK14MAPK13CDK8CCNCMAPK12 | |
| SCHEMBL15007941 | 0.84 | MAPK14 (0.56) | MAPK14MAPK13CDK8CCNCMAPK12 | |
| SCHEMBL3190583 | 0.84 | MAPK14 (0.58) | MAPK14MAPK13CDK8CCNCMAPK12 | |
| SCHEMBL3179284 | 0.83 | CDK8 (0.52) | MAPK14MAPK13CDK8CCNCMAPK12 | |
| SCHEMBL2361698 | 0.83 | JAK2 (0.66) | MAPK14MAPK13MAPK12MAPK11JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9527846-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-12-27 | — | — | US | disclosed |
| EP-2788349-B1 | KINASE INHIBITORS | CHIESI FARMA SPA (IT) | 2016-10-26 | — | — | EP | disclosed |
| US-20160229852-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-08-11 | — | — | US | disclosed |
| US-9315503-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-04-19 | — | — | US | disclosed |
| US-20150344475-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-12-03 | — | — | US | disclosed |
| US-9145413-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-09-29 | — | — | US | disclosed |
| US-9139584-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-09-22 | — | — | US | disclosed |
| US-20150080375-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-03-19 | — | — | US | disclosed |
| US-8907094-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-12-09 | — | — | US | disclosed |
| US-20140323470-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-10-30 | — | — | US | disclosed |
| EP-2788349-A1 | KINASE INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2014-10-15 | — | — | EP | disclosed |
| WO-2013083604-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-06-13 | — | — | WO | disclosed |
| US-20130150343-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-06-13 | — | — | US | disclosed |
| US-8202899-B2 | Pyrazole urea derivatives used as kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20100331385-A1 | PYRAZOLE UREA DERIVATIVES USED AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344475-A1 | KINASE INHIBITORS | MAPK1, MAP3K1, MAPK6 | MAPK14 33/4885MAPK13 20/4885CDK8 321/4885 |
| US-20160229852-A1 | KINASE INHIBITORS | MAPK1, MAP3K1, MAPK6 | MAPK14 33/4885MAPK13 20/4885CDK8 321/4885 |
| US-20150080375-A1 | KINASE INHIBITORS | MAPK1, MAP3K1, MAPK6 | MAPK14 33/4885MAPK13 20/4885CDK8 321/4885 |
| US-20140323470-A1 | KINASE INHIBITORS | MAPK1, MAP3K1, MAPK6 | MAPK14 33/4885MAPK13 20/4885CDK8 321/4885 |
| US-20130150343-A1 | KINASE INHIBITORS | MAPK1, MAP3K1, MAPK6 | MAPK14 33/4885MAPK13 20/4885CDK8 321/4885 |
| US-20100331385-A1 | PYRAZOLE UREA DERIVATIVES USED AS KINASE INHIBITORS | MAP3K1, MAP3K19, MAP3K13 | MAPK14 105/4885MAPK13 100/4885CDK8 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.